Seizure disorders:
Indications for: BRIVIACT INJECTION
Partial-onset seizures, as monotherapy or adjunctive treatment; may be used when oral administration is temporarily not feasible.
Adult Dosage:
Interchangeable with other forms. Tabs: swallow whole with liquid. Oral soln: use calibrated measuring device. May also give via nasogastric or gastrostomy tube. IV: administer over 2–15mins; limit to 4 consecutive days of treatment. All: adjust dosage based on response and tolerability. ≥16yrs: initially 50mg twice daily; usual maintenance: 25–100mg twice daily. Hepatic impairment: initially 25mg twice daily; max 75mg twice daily. Concomitant rifampin: double brivaracetam dosage.
Children Dosage:
<1 month: not established. Interchangeable with other forms. Tabs: swallow whole with liquid. Oral soln: use calibrated measuring device. May also give via nasogastric or gastrostomy tube. IV: administer over 2–15mins; limit to 4 consecutive days of treatment. All: adjust dosage based on response and tolerability. 1 month–<16yrs (<11kg): initially 0.75–1.5mg/kg twice daily; usual maintenance: 0.75–3mg/kg twice daily; (11–<20kg): initially 0.5–1.25mg/kg twice daily; usual maintenance: 0.5–2.5mg/kg twice daily; (20–<50kg): initially 0.5–1mg/kg twice daily; usual maintenance: 0.5–2mg/kg twice daily; (≥50kg): initially 25–50mg twice daily; usual maintenance: 25–100mg twice daily. Hepatic impairment (<11kg): initially 0.75mg/kg twice daily; max 2.25mg/kg twice daily; (11–<50kg): initially 0.5mg/kg twice daily; max 2mg/kg twice daily (11–<20kg) or 1.5mg/kg twice daily (20–<50kg); (≥50kg): as Adult. Concomitant rifampin: double brivaracetam dosage.
BRIVIACT INJECTION Warnings/Precautions:
Increased risk of suicidal behavior or ideation; monitor for clinical worsening and/or any unusual changes. Monitor for neurological and psychiatric adverse reactions. Discontinue if hypersensitivity reactions occur. Hepatic impairment: adjust dose (see Adult, Children). End-stage renal disease undergoing dialysis: not recommended. Avoid abrupt cessation. Pregnancy. Nursing mothers.
See Also:
BRIVIACT INJECTION Classification:
Antiepileptic.
BRIVIACT INJECTION Interactions:
Antagonized by rifampin. Concomitant carbamazepine: may consider dose reduction if intolerant. May potentiate phenytoin; monitor phenytoin levels when adding or discontinuing brivaracetam from ongoing therapy. Concomitant levetiracetam: no added benefit.
Adverse Reactions:
Somnolence/sedation, dizziness, fatigue, nausea/vomiting; hematologic abnormalities.
Note:
To enroll in the North American Antiepileptic Drug Pregnancy Registry call (888) 233-2334.
Generic Drug Availability:
NO
How Supplied:
Tabs—60; Oral soln—300mL; Single-dose vials—10
